https://orcid.org/0000-0002-1519-8828
References
- Akhtar S. Pharmacological considerations in the elderly. Curr Opin Anaesthesiol. 2018;31(1):11–18.
- Blasiak A, Khong J, Curate. KT, et al. Medicine with Artificial Intelligence. SLAS Technol. 2020;25(2):95–105.
- Reeve E, Trenaman SC, Rockwood K, et al. Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin Drug Metab Toxicol. 2017;13(6):651–668.
- Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs RD. 2016;16(4):303–316.
- Bauer L. Applied Clinical Pharmacokinetics. 2nd ed ed. New York: McGraw-Hill Medical; 2008.
- Ogawa R, Stachnik JM, Echizen H. Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously). Clin Pharmacokinet. 2013;52(3):169–185.
- Ogawa R, Stachnik JM, Echizen H. Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally). Clin Pharmacokinet. 2014;53(12):1083–1114.
- Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420.
- Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–1161.
- Nolin TDA. Synopsis of clinical pharmacokinetic alterations in advanced CKD. Semin Dial. 2015;28(4):325–329.
- Schumacher GE. Practical pharmacokinetic techniques for drug consultation and evaluation. II. A perspective on the renal impaired patient. Am J Hosp Pharm. 1973;30(9):824–830.
- Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99–110.
- Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.
- Nakajima K, Kusuoka H, Nishimura S, et al. Normal limits of ejection fraction and volumes determined by gated SPECT in clinically normal patients without cardiac events: a study based on the J-ACCESS database. Eur J Nucl Med Mol Imaging. 2007;34(7):1088–1096.
- Rains CP, Bryson HM, Peters DH. Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1995;49(4):577–617.
- Ceftazidime 1g Powder for solution for injection - Summary of Product Characteristics (SmPC) - (emc) [Internet]. [cited 2020 Oct 24]. Available from: https://www.medicines.org.uk/emc/medicine/21129
- Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2013;68(4):900–906.
- Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs. 2011;71(4):489–514.